Jim Hoffman: Exploring Extracorporeal Strategies to Target NETs in Cardiovascular Disease
Jim Hoffman, Former Technical Advisor at Cygnus Technologies, LLC, shared Apherese ForschungsInstitut – AFI’s post on LinkedIn, adding:
”Lp(a) does not act alone to help facilitate potentially life-threatening occlusive atheromas. Other factors, such as NETosis dysfunction and poor NET clearance, are likely at play, increasing the risk of CVD, heart failure, MI, and strokes.
Here are two other extracorporeal methods that target elevated extracellular chromatin/NETs that I believe should be trialed for potentially reversing diet and drug-refractory atherogenesis. They are simpler to perform and could be more efficacious than H.E.L.P. apheresis and other extracorporeal methods of lipid lowering.
A Novel Role for Lipoprotein(a) in Potentiating Neutrophil Extracellular Trap Formation.
More research linking NETosis dysfunction to atherosclerosis progression and atheroma development can be found
Quoting Apherese ForschungsInstitut – AFI’s post:
”Elevated Lipoprotein(a) is a major, genetically determined driver of cardiovascular risk, yet it remains largely untouched by traditional lifestyle changes and statins.
A recent review in the European Heart Journal titled ‘Lipoprotein(a)-lowering therapies: a promising future’ highlights the evolving landscape of treatment.
At the Apherese Forschungsinstitut, we closely follow these developments. Phase III trials of RNA-based therapies specifically targeting Lp(a) are currently underway. Until these new drugs reach the market and prove long-term outcomes, Lipoprotein Apheresis continues to be the life-saving ‘gold standard’ for patients with extreme Lp(a) elevation and progressive ASCVD.
In the current therapeutic landscape, Lipoprotein Apheresis remains the only established and highly effective method to significantly reduce Lp(a) levels and mitigate cardiovascular events in high-risk patients.”
Title: Lipoprotein(a)-lowering therapies: a promising future
Authors: Jingwen Zhang, Ann Marie Navar, Lale Tokgozoglu
Read the Full Article on Apherese ForschungsInstitut – AFI
Stay updated on all scientific advances with Hemostasis Today.
-
Jun 11, 2026, 08:35Mohamed Reda: CBC Report – More Than Just Numbers
-
Jun 11, 2026, 07:59Uday Sankar Akash Vankayala: Key Findings on IBD-Associated VTE Phenotypes and Inpatient Burden
-
Jun 11, 2026, 07:41Zia Ullah: Hidden Cerebral Venous Sinus Thrombosis After Dengue Recovery
-
Jun 11, 2026, 07:24Aaron Rodriguez Calienes: RESISTANT Registry Provides Reassuring Safety Data for Acute Intracranial Stenting
-
Jun 11, 2026, 07:17Mbunya. S. Misiani: From the WFH Congress to Meaningful Change for Patients with Bleeding Disorders Worldwide
-
Jun 11, 2026, 07:06Bernard Slater Jr.: Hemophilia B Reminds You that No Matter How Strong You Are, You Are Still Human
-
Jun 11, 2026, 05:11Daniel I McIsaac: Less Blood Loss and No Excess VTE with Tranexamic Acid in High-Risk Surgery
-
Jun 11, 2026, 05:03Aymeric Couturier: Lessons from the TRACK Trial on Anticoagulation in Advanced CKD
-
Jun 11, 2026, 04:53Umut Kocabas: Current Practice and Guideline Adherence on Cancer-Associated Thrombosis in Turkey